EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pyridoxal‐5′‐phosphate: A cost‐effective treatment candidate for hypertensive patients?

Michaela Lellig iD, Mariano Rodríguez iD, Rodrigo López-Baltanás, Juliane Hermann, Julia Wollenhaupt iD, Heidi Noels iD, Walter Zidek, Martin Tepel iD, Felix Mahfoud iD, Joachim Jankowski iD, Juan R Muñoz-Castañeda iD, Vera Jankowski iD

Journal of Internal Medicine · 2024

DOI: 10.1111/joim.20015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Michaela Lellig und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecular Cardiovascular Research IMCAR, RWTH Aachen University, Aachen, Germany. Hauptthemen laut MEDLINE: Pyridoxal Phosphate, Vitamin B Complex, Hypertension, Angiotensin II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Center, InteraKD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Because angiotensin (Ang) II is an essential vasoconstrictive peptide, we analyzed the impact of its post‐translational modification to pyruvamide–Ang II (Ang P) by pyridoxal‐5′‐phosphate (PLP) on blood pressure. PLP is a less expensive vitamin B 6 derivative and, therefore, could be a cost‐effective drug against hypertension.

Methods

Effect of Ang P on calcium ion entry into vascular smooth muscle cells (VSMCs) was analyzed. Binding affinity of Ang P to angiotensin II type 1 receptor (AT 1 R) was measured. Vasoconstrictive effect of Ang P was investigated using the bioassay of isolated perfused rat kidneys. Spontaneously hypertensive rats (SHR) were administered PLP. Additionally, Wistar Kyoto rats (WKY) received Ang II and PLP. Blood pressure was measured time‐dependently.

Results

Ang II, incubated with PLP, was post‐translationally modified to Ang P. Calcium ion entry in VSMCs was significantly lower with Ang P compared to Ang II. Binding affinity of Ang P to AT 1 R was lower compared to Ang II. Perfusion pressure of isolated perfused rat kidneys increased less by Ang P than by Ang II. Blood pressure of SHR treated with PLP decreased significantly. Blood pressure of WKY rats treated with Ang II was increased to hypertensive values, whereas blood pressure of WKY rats cotreated with Ang II and PLP was not.

Conclusion

PLP induces a post‐translational modification of Ang II decreasing blood pressure in rats. Assuming that increased PLP intake in the form of vitamin B 6 might reduce blood pressure in hypertensive patients, PLP might be a cost‐effective drug against hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pyridoxal PhosphateVitamin B ComplexHypertensionAngiotensin IIProtein Processing, Post-TranslationalHumansCells, CulturedFemaleAnimalsRatsRats, Inbred SHRRats, Inbred WKYIn Vitro TechniquesReceptor, Angiotensin, Type 1Myocytes, Smooth MuscleAortaPerfusionBlood PressurePyruvates

Stichwörter der Autor:innen

angiotensin IIhypertensionpyridoxal‐5′‐phosphatepyruvamide–angiotensin IIrenin–angiotensin–aldosterone systemvitamin B6

Substanzen

Pyridoxal PhosphateVitamin B ComplexAngiotensin IIReceptor, Angiotensin, Type 1pyruvamidePyruvates

Autor:innen und Institutionen

  • Institute for Molecular Cardiovascular Research IMCAR, RWTH Aachen University, Aachen, Germany.
  • Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain.
  • Department of Medicine, School of Medicine, University of Cordoba, Cordoba, Spain.
  • Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain.
  • Department of Biochemistry, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
  • Meoclinic, Berlin, Germany.

ORCID-Profile: Michaela Lellig, Mariano Rodríguez, Julia Wollenhaupt, Heidi Noels, Martin Tepel, Felix Mahfoud, Joachim Jankowski, Juan R Muñoz-Castañeda, Vera Jankowski

Förderung

  • Deutsche Forschungsgemeinschaft
  • Transregional Collaborative Research Center
  • InteraKD
  • KidneySign
  • COST Action
  • Spanish government
  • Instituto de Salud Carlos III
  • European Funds

Zitieren

APA

Lellig, M., Rodríguez, M., López-Baltanás, R., Hermann, J., Wollenhaupt, J., Noels, H., Zidek, W., Tepel, M., Mahfoud, F., Jankowski, J., Muñoz-Castañeda, J. R., & Jankowski, V. (2024). Pyridoxal‐5′‐phosphate: A cost‐effective treatment candidate for hypertensive patients?. Journal of Internal Medicine. https://doi.org/10.1111/joim.20015

Vancouver

Lellig M, Rodríguez M, López-Baltanás R, Hermann J, Wollenhaupt J, Noels H, et al. Pyridoxal‐5′‐phosphate: A cost‐effective treatment candidate for hypertensive patients?. Journal of Internal Medicine. 2024. doi:10.1111/joim.20015

BibTeX
@article{Lellig2024,
  author = {Lellig, Michaela and Rodríguez, Mariano and López-Baltanás, Rodrigo and Hermann, Juliane and Wollenhaupt, Julia and Noels, Heidi and Zidek, Walter and Tepel, Martin and Mahfoud, Felix and Jankowski, Joachim and Muñoz-Castañeda, Juan R and Jankowski, Vera},
  title = {Pyridoxal‐5′‐phosphate: A cost‐effective treatment candidate for hypertensive patients?},
  journal = {Journal of Internal Medicine},
  year = {2024},
  doi = {10.1111/joim.20015}
}
Kostenlos starten →